{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T21:09:02Z","timestamp":1788815342935,"version":"build-2803163510"},"reference-count":65,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,8,19]],"date-time":"2027-08-19T00:00:00Z","timestamp":1818633600000},"content-version":"am","delay-in-days":352,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ijgc.2026.104898","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:58:52Z","timestamp":1785772732000},"page":"104898","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["From genetic testing to prevention: an integrated clinical pathway for hereditary risk assessment in tubo-ovarian cancer"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9395-0627","authenticated-orcid":false,"given":"David","family":"Viveros-Carre\u00f1o","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4240-2227","authenticated-orcid":false,"given":"Nathalia","family":"Mora-Soto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Beshar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1165-0661","authenticated-orcid":false,"given":"Nuria","family":"Agust\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Mart\u00ednez-Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0589-2696","authenticated-orcid":false,"given":"Andreina","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7093-6862","authenticated-orcid":false,"given":"Alessandro","family":"Buda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Rauh-Hain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Pareja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijgc.2026.104898_bib1","unstructured":"Genetic\/familial high-risk assessment: breast, ovarian, pancreatic, and prostate, version 3.2026. National Comprehensive Cancer Network. Accessed March 10, 2026. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_bopp.pdf."},{"issue":"11","key":"10.1016\/j.ijgc.2026.104898_bib2","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1200\/JCO.19.02960","article-title":"Germline and somatic tumor testing in epithelial ovarian cancer: ASCO guideline","volume":"38","author":"Konstantinopoulos","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijgc.2026.104898_bib3","article-title":"Guideline Committee. Ovarian cancer: identifying and managing familial and genetic risk-summary of new NICE guidance","volume":"385","author":"Slade","year":"2024","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104898_bib4","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.annonc.2022.10.004","article-title":"Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline","volume":"34","author":"Sessa","year":"2023","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.ijgc.2026.104898_bib5","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1136\/ijgc-2024-005756","article-title":"British Gynaecological Cancer Society\/British Association of Gynaecological Pathology consensus for genetic testing in epithelial ovarian cancer in the United Kingdom","volume":"34","author":"Leung","year":"2024","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104898_bib6","doi-asserted-by":"crossref","DOI":"10.6004\/jnccn.2022.7257","article-title":"Nationwide trends and determinants of germline BRCA1\/2 testing in patients with breast and ovarian cancer","volume":"21","author":"Lau-Min","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104898_bib7","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104898_bib8","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1001\/jamaoncol.2015.5495","article-title":"Inherited mutations in women with ovarian carcinoma","volume":"2","author":"Norquist","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijgc.2026.104898_bib9","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1146\/annurev-genom-083118-015253","article-title":"Population screening for inherited predisposition to breast and ovarian cancer","volume":"21","author":"Manchanda","year":"2020","journal-title":"Annu Rev Genomics Hum Genet."},{"issue":"21","key":"10.1016\/j.ijgc.2026.104898_bib10","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1200\/JCO.24.00662","article-title":"Selection of germline genetic testing panels in patients with cancer: ASCO guideline","volume":"42","author":"Tung","year":"2024","journal-title":"J Clin Oncol"},{"issue":"35","key":"10.1016\/j.ijgc.2026.104898_bib11","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1200\/JCO.22.00303","article-title":"Cascade testing for hereditary cancer syndromes: should we move toward direct relative contact? A systematic review and meta-analysis","volume":"40","author":"Frey","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijgc.2026.104898_bib12","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ejogrb.2024.06.025","article-title":"British Gynaecological Cancer Society (BGCS) ovarian, tubal and primary peritoneal cancer guidelines: recommendations for practice update 2024","volume":"300","author":"Moss","year":"2024","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"10290","key":"10.1016\/j.ijgc.2026.104898_bib13","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1016\/S0140-6736(21)00731-5","article-title":"Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial","volume":"397","author":"Menon","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ijgc.2026.104898_bib14","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1097\/AOG.0000000000003562","article-title":"Hereditary cancer syndromes and risk assessment: ACOG committee opinion, number 793","volume":"134","year":"2019","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ijgc.2026.104898_bib15","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ygyno.2023.12.010","article-title":"Germline and somatic testing for ovarian cancer: an SGO clinical practice statement","volume":"181","author":"Gressel","year":"2024","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104898_bib16","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.annonc.2023.11.015","article-title":"ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease","volume":"35","author":"Ledermann","year":"2024","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104898_bib17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2014.09.009","article-title":"Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions","volume":"136","author":"Lancaster","year":"2015","journal-title":"Gynecol Oncol"},{"issue":"23","key":"10.1016\/j.ijgc.2026.104898_bib18","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"issue":"15","key":"10.1016\/j.ijgc.2026.104898_bib19","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.2013.53.2820","article-title":"Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation","volume":"32","author":"Finch","year":"2014","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104898_bib20","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/jnci\/djn442","article-title":"Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers","volume":"101","author":"Rebbeck","year":"2009","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104898_bib21","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41436-019-0596-9","article-title":"Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch syndrome Database","volume":"22","author":"Dominguez-Valentin","year":"2020","journal-title":"Genet Med"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104898_bib22","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/s41436-020-01029-1","article-title":"Risk-reducing hysterectomy and bilateral salpingo-oophorectomy in female heterozygotes of pathogenic mismatch repair variants: a Prospective Lynch syndrome Database report","volume":"23","author":"Dominguez-Valentin","year":"2021","journal-title":"Genet Med"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104898_bib23","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10689-012-9591-x","article-title":"EPCAM deletion carriers constitute a unique subgroup of Lynch syndrome patients","volume":"12","author":"Ligtenberg","year":"2013","journal-title":"Fam Cancer"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104898_bib24","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s10549-021-06258-9","article-title":"Double heterozygotes of BRCA1\/BRCA2 and mismatch repair gene pathogenic variants: case series and clinical implications","volume":"188","author":"Laish","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ijgc.2026.104898_bib25","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ygyno.2022.12.008","article-title":"Mismatch-repair deficiency, microsatellite instability, and Lynch syndrome in ovarian cancer: a systematic review and meta-analysis","volume":"170","author":"Mitric","year":"2023","journal-title":"Gynecol Oncol"},{"issue":"12","key":"10.1016\/j.ijgc.2026.104898_bib26","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1093\/jnci\/djaa030","article-title":"Ovarian and breast cancer risks associated with pathogenic variants in RAD51C and RAD51D","volume":"112","author":"Yang","year":"2020","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"10.1016\/j.ijgc.2026.104898_bib27","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv214","article-title":"Germline mutations in the BRIP1, BARD1, PALB2, and NBN genes in women with ovarian cancer","volume":"107","author":"Ramus","year":"2015","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.ijgc.2026.104898_bib28","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1136\/jmg-2022-108898","article-title":"UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes: RAD51C, RAD51D, BRIP1 and PALB2","volume":"60","author":"Hanson","year":"2023","journal-title":"J Med Genet"},{"issue":"11","key":"10.1016\/j.ijgc.2026.104898_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2025.101557","article-title":"Management of individuals with heterozygous germline pathogenic variants in RAD51C, RAD51D, and BRIP1: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)","volume":"27","author":"Ngeow","year":"2025","journal-title":"Genet Med"},{"issue":"7","key":"10.1016\/j.ijgc.2026.104898_bib30","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1200\/JCO.19.01907","article-title":"Cancer risks associated with germline PALB2 pathogenic variants: an international study of 524 families","volume":"38","author":"Yang","year":"2020","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ijgc.2026.104898_bib31","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/s41436-021-01151-8","article-title":"Management of individuals with germline variants in PALB2: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)","volume":"23","author":"Tischkowitz","year":"2021","journal-title":"Genet Med"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104898_bib32","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.ygyno.2019.01.027","article-title":"Large-scale meta-analysis of mutations identified in panels of breast\/ovarian cancer-related genes - Providing evidence of cancer predisposition genes","volume":"153","author":"Suszynska","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2026.104898_bib33","series-title":"GeneReviews(\u00ae)","article-title":"DICER1-related tumor predisposition","author":"Schultz","year":"1993"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104898_bib34","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/PAP.0000000000000515","article-title":"DICER1-associated gynecologic neoplasms: an update and review","volume":"33","author":"Kim","year":"2026","journal-title":"Adv Anat Pathol"},{"issue":"5","key":"10.1016\/j.ijgc.2026.104898_bib35","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/ng.2931","article-title":"Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type","volume":"46","author":"Witkowski","year":"2014","journal-title":"Nat Genet"},{"issue":"5","key":"10.1016\/j.ijgc.2026.104898_bib36","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/ng.2928","article-title":"Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4","volume":"46","author":"Ramos","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.ijgc.2026.104898_bib37","series-title":"GeneReviews(\u00ae)","article-title":"Peutz-Jeghers Syndrome","author":"McGarrity","year":"1993"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104898_bib38","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.path.2016.01.006","article-title":"Peutz-Jeghers syndrome: pathobiology, pathologic manifestations, and suggestions for recommending genetic testing in pathology reports","volume":"9","author":"Meserve","year":"2016","journal-title":"Surg Pathol Clin."},{"issue":"6","key":"10.1016\/j.ijgc.2026.104898_bib39","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/1471-0528.17675","article-title":"Patient decision aids in mainstreaming genetic testing for women with ovarian cancer: a prospective cohort study","volume":"131","author":"Sobocan","year":"2024","journal-title":"BJOG"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104898_bib40","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.ajog.2025.04.044","article-title":"Uptake and patient-related outcomes of mainstreaming genetic testing: a systematic review and meta-analysis","volume":"233","author":"Kalra","year":"2025","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ijgc.2026.104898_bib41","doi-asserted-by":"crossref","DOI":"10.1038\/srep29506","article-title":"Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients","volume":"6","author":"George","year":"2016","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104898_bib42","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s10689-016-9956-7","article-title":"Outcomes of retesting BRCA negative patients using multigene panels","volume":"16","author":"Yadav","year":"2017","journal-title":"Fam Cancer"},{"issue":"21","key":"10.1016\/j.ijgc.2026.104898_bib43","doi-asserted-by":"crossref","first-page":"5210","DOI":"10.1002\/cncr.27556","article-title":"Clinical significance of large rearrangements in BRCA1 and BRCA2","volume":"118","author":"Judkins","year":"2012","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.ijgc.2026.104898_bib44","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.annonc.2020.08.2102","article-title":"ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer","volume":"31","author":"Miller","year":"2020","journal-title":"Ann Oncol"},{"issue":"17","key":"10.1016\/j.ijgc.2026.104898_bib45","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.3390\/cancers13174344","article-title":"Implementation of Multigene Germline and Parallel Somatic Genetic Testing in Epithelial Ovarian Cancer: SIGNPOST Study","volume":"13","author":"Chandrasekaran","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104898_bib46","doi-asserted-by":"crossref","DOI":"10.1080\/01443615.2025.2594629","article-title":"Consent model for tumour genetic testing in ovarian cancer","volume":"45","author":"Fierheller","year":"2025","journal-title":"J Obstet Gynaecol"},{"issue":"10","key":"10.1016\/j.ijgc.2026.104898_bib47","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/pon.3537","article-title":"Understanding of BRCA1\/2 genetic tests results: the importance of objective and subjective numeracy","volume":"23","author":"Hanoch","year":"2014","journal-title":"Psychooncology"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104898_bib48","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10549-010-0923-y","article-title":"No evidence of excess breast cancer risk among mutation-negative women from BRCA mutation-positive families","volume":"125","author":"Korde","year":"2011","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"10.1016\/j.ijgc.2026.104898_bib49","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1007\/s10897-018-0241-9","article-title":"Factors Influencing Clinical Follow-Up for Individuals with a Personal History of Breast and\/or Ovarian Cancer and Previous Uninformative BRCA1 and BRCA2 Testing","volume":"27","author":"Chadwell","year":"2018","journal-title":"J Genet Couns"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104898_bib50","doi-asserted-by":"crossref","first-page":"502","DOI":"10.3390\/genes14020502","article-title":"Unexpected findings in hereditary breast and ovarian cancer syndrome: low-level constitutional mosaicism in BRCA2","volume":"14","author":"Hidalgo","year":"2023","journal-title":"Genes (Basel."},{"issue":"5","key":"10.1016\/j.ijgc.2026.104898_bib51","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"issue":"12","key":"10.1016\/j.ijgc.2026.104898_bib52","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/jama.2018.13152","article-title":"Prevalence of Variant Reclassification Following Hereditary Cancer Genetic Testing","volume":"320","author":"Mersch","year":"2018","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.ijgc.2026.104898_bib53","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1136\/jmedgenet-2016-103800","article-title":"Specifying the ovarian cancer risk threshold of 'premenopausal risk-reducing salpingo-oophorectomy' for ovarian cancer prevention: a cost-effectiveness analysis","volume":"53","author":"Manchanda","year":"2016","journal-title":"J Med Genet"},{"issue":"6","key":"10.1016\/j.ijgc.2026.104898_bib54","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1136\/ijgc-2023-004377","article-title":"TUBectomy with delayed oophorectomy as an alternative to risk-reducing salpingo-oophorectomy in high-risk women to assess the safety of prevention: the TUBA-WISP II study protocol","volume":"33","author":"Steenbeek","year":"2023","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104898_bib55","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1158\/1055-9965.EPI-20-1319","article-title":"CanRisk Tool-a web interface for the prediction of breast and ovarian cancer risk and the likelihood of carrying genetic pathogenic variants","volume":"30","author":"Carver","year":"2021","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"8","key":"10.1016\/j.ijgc.2026.104898_bib56","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1038\/s41436-018-0406-9","article-title":"BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors","volume":"21","author":"Lee","year":"2019","journal-title":"Genet Med"},{"issue":"7","key":"10.1016\/j.ijgc.2026.104898_bib57","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1136\/jmedgenet-2021-107904","article-title":"Comprehensive epithelial tubo-ovarian cancer risk prediction model incorporating genetic and epidemiological risk factors","volume":"59","author":"Lee","year":"2022","journal-title":"J Med Genet"},{"issue":"9","key":"10.1016\/j.ijgc.2026.104898_bib58","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1038\/s41416-024-02851-z","article-title":"Validation of the BOADICEA model for epithelial tubo-ovarian cancer risk prediction in UK Biobank","volume":"131","author":"Yang","year":"2024","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ijgc.2026.104898_bib59","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1471-2350-9-116","article-title":"Selecting a BRCA risk assessment model for use in a familial cancer clinic","volume":"9","author":"Panchal","year":"2008","journal-title":"BMC Med Genet"},{"issue":"7","key":"10.1016\/j.ijgc.2026.104898_bib60","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw302","article-title":"Evaluation of polygenic risk scores for breast and ovarian cancer risk prediction in BRCA1 and BRCA2 mutation carriers","volume":"109","author":"Kuchenbaecker","year":"2017","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104898_bib61","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1097\/GRF.0000000000000895","article-title":"Uptake of cascade genetic testing for hereditary breast and ovarian cancer: a systematic review and meta-analysis","volume":"67","author":"Ahsan","year":"2024","journal-title":"Clin Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104898_bib62","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.ygyno.2021.12.027","article-title":"Hospital-based ovarian cancer patient traceback program results in minimal genetic testing uptake","volume":"164","author":"Weinmann","year":"2022","journal-title":"Gynecol Oncol"},{"issue":"18","key":"10.1016\/j.ijgc.2026.104898_bib63","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1200\/JCO.21.02108","article-title":"TRACEBACK: testing of historical tubo-ovarian cancer patients for hereditary risk genes as a cancer prevention strategy in family members","volume":"40","author":"Delahunty","year":"2022","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ijgc.2026.104898_bib64","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1136\/ijgc-2020-002118","article-title":"Facilitated cascade testing (FaCT): a randomized controlled trial","volume":"31","author":"Nitecki","year":"2021","journal-title":"Int J Gynecol Cancer"},{"issue":"2 d","key":"10.1016\/j.ijgc.2026.104898_bib65","article-title":"Cost-effectiveness of unselected multigene germline and somatic genetic testing for epithelial ovarian cancer","volume":"22","author":"Manchanda","year":"2024","journal-title":"J Natl Compr Canc Netw"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26004299?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26004299?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T20:45:46Z","timestamp":1788813946000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X26004299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":65,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1048891X26004299"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104898","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From genetic testing to prevention: an integrated clinical pathway for hereditary risk assessment in tubo-ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104898","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Society of Gynaecological Oncology and the International Gynecologic Cancer Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104898"}}